Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Locus Cell CoROCO:6891 -0.50%22 Gross Margin % is 44.29% as of Dec. 2025, which is 26% below its 10-year median of 60.07. GuruFocus rates ROCO:6891 with a GF Score™ of 22/100 and a GF Value™ of NT$778.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 735 Biotechnology companies, Locus Cell Co ranks worse than 60.14% on this metric.
Locus Cell Co (ROCO:6891) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Locus Cell Co had a gross margin of 44.29% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Locus Cell Co Gross Margin % Related Terms
Locus Cell Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Locus Cell Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6891 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Locus Cell Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Locus Cell Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Locus Cell Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Locus Cell Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Locus Cell Co (ROCO:6891) has a Gross Margin % of 44.29% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Locus Cell Co and its competitors. This is 26% below median its historical median of 60.07. Over the past decade, Locus Cell Co's Gross Margin % has ranged from 42.12 to 83.17. According to the industry distribution chart, Locus Cell Co ranks #442 out of 735 companies in the Biotechnology industry, placing it in the top 60.1%.
Is Locus Cell Co's Gross Margin % too high?
Locus Cell Co's current Gross Margin % of 44.29% is 26% below median its 10-year median of 60.07. Over the past 10 years, this metric has ranged from a low of 42.12 to a high of 83.17. The Biotechnology industry median Gross Margin % is 60.91. Locus Cell Co's value of 44.29% is 27.3% below this industry median. Based on the distribution chart, Locus Cell Co ranks #442 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Locus Cell Co has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Locus Cell Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Locus Cell Co ranks #442 out of 735 companies for Gross Margin %. This places Locus Cell Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Locus Cell Co's value of 44.29% is 27.3% below this benchmark. Historically, Locus Cell Co's own Gross Margin % has ranged from 42.12 to 83.17 over the past decade. While the company's 10-year median is 60.07 vs. the industry median of 60.91, Locus Cell Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Locus Cell Co's current Gross Margin % of 44.29% is 27.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Locus Cell Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Locus Cell Co's current Gross Margin % is 44.29%, which is 26% below median its own 10-year median of 60.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Locus Cell Co stock overvalued right now?
Based on GuruFocus' analysis, Locus Cell Co (ROCO:6891) is currently considered Possible Value Trap. The stock's GF Value™ is NT$778.63, compared to a current price of NT$38.65 — trading 95% below its estimated fair value. The current Gross Margin % is 44.29%, which is 26% below median its 10-year median of 60.07 and 27.3% below the Biotechnology industry median of 60.91. Locus Cell Co's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Locus Cell Co (ROCO:6891), the current Gross Margin % is 44.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Locus Cell Co (ROCO:6891) Overvalued in 2026?
Based on GuruFocus' analysis, Locus Cell Co stock appears to be undervalued.
The current stock price of NT$38.65 is trading 95% below its estimated GF Value™ of NT$778.63.
GuruFocus considers Locus Cell Co to be Possible Value Trap.
Key valuation signals for ROCO:6891:
Gross Margin %: 44.29% (26% below median its 10-year median of 60.07)
GF Value™: NT$778.63 vs. price of NT$38.65 (95% below fair value)
Industry Position: 27.3% below the Biotechnology median (#442 of 735)
No single metric tells the full story. See the ROCO:6891 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6891 has been successfully added to your 
